Skip to navigation Skip to content

Cystic fibrosis (CF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051113

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ivacaftor, lumacaftor+ivacaftor, tezacaftor+ivacaftor and elexacaftor+tezacaftor+ivacaftor for patients with cystic fibrosis (CF).

CF and listing dates

CF is a condition that affects the cells that produce mucus, sweat and digestive juices. It causes these fluids to become thick and sticky. They then plug up tubes, ducts and passageways leading to airway and digestive issues.

Listing dates:

  • ivacaftor - 1 December 2014
  • lumacaftor+ivacaftor - 1 October 2018
  • tezacaftor+ivacaftor - 1 December 2019
  • elexacaftor+tezacaftor+ivacaftor - 1 April 2022

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs